drugset / Trial / NCT06745687
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
Not yet recruiting
20 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Keymed Biosciences Co.Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of CM-336, which is a BCMA/CD3 BiTE, in the treatment of high risk smoldering multiple myeloma.
Timeline
- Start
- 2024-12-30
- Primary completion
- 2026-08-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM336 | Monoclonal antibody | 80 mg | Subcutaneous |
| Subject | CM336 | Monoclonal antibody | 160 mg | Subcutaneous |